← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Other monoclonal antibodies and antibody drug conjugates
catumaxomab
L01FX03
Forms & Strengths
- Intraperitoneal infusion: 10 micrograms/mL in 1 mL single-use vial
Adult Dosing
- Malignant ascites: Intraperitoneal infusion on days 0, 3, 7, and 10
- Dose escalation protocol: 10 mcg (Day 0), 20 mcg (Day 3), 50 mcg (Day 7), and 150 mcg (Day 10)
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible
Mechanism of Action
- Rat-mouse hybrid monoclonal trifunctional antibody
- Binds to epithelial cell adhesion molecule (EpCAM) on tumor cells and CD3 on T cells
- Fc region binds to Fcgamma receptor-positive accessory cells (macrophages, dendritic cells, natural killer cells)
- Results in T-cell-mediated lysis, antibody-dependent cellular cytotoxicity, and phagocytosis of tumor cells
Contraindications
- Hypersensitivity to catumaxomab or murine proteins
- Active systemic infections
Adverse Reactions
- Abdominal pain
- Nausea and vomiting
- Pyrexia
- Fatigue
- Cytokine release syndrome
- Lymphopenia
- Transaminasemia
- Diarrhea
Drug Interactions
- Immunosuppressants may reduce the efficacy of catumaxomab
- Avoid concurrent use of other systemic antineoplastic monoclonal antibodies unless specifically indicated
Curated Content: Needs Vetting Before Put to Clinical Use